Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - dacomitinib monohydrate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - dacominitib monohydrate -

Canada - English - Health Canada

sanis health inc - alfuzosin hydrochloride - tablet (extended-release) - 10mg - alfuzosin hydrochloride 10mg - selective alfa-1-adrenergic blocking agents

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

pfizer laboratories limited, kenya - dacomitinib - tablets - 45

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

pfizer laboratories limited, kenya - dacomitinib - tablets - 15

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals nj, llc - primaquine phosphate (unii: h0982hf78b) (primaquine - unii:mvr3634gx1) - primaquine 15 mg

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - primaquine phosphate (unii: h0982hf78b) (primaquine - unii:mvr3634gx1) - primaquine 15 mg - primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria. severe glucose-6-phosphate dehydrogenase (g6pd) deficiency (see warnings). pregnant women (see warnings, usage in pregnancy). primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. the drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. similarly, primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased.

United States - English - NLM (National Library of Medicine)

avkare - primaquine phosphate (unii: h0982hf78b) (primaquine - unii:mvr3634gx1) - primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria. severe glucose-6-phosphate dehydrogenase (g6pd) deficiency (see warnings). pregnant women (see warnings, usage in pregnancy). primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. the drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. similarly, primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased.